| Stage at diagnosis and ovarian cancer survival: Evidence from the International Cancer Benchmarking Partnership. | |
| | |
MedLine Citation:
|
PMID: 22750127 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE: We investigate what role stage at diagnosis bears in international differences in ovarian cancer survival. METHODS: Data from population-based cancer registries in Australia, Canada, Denmark, Norway, and the UK were analysed for 20,073 women diagnosed with ovarian cancer during 2004-7. We compare the stage distribution between countries and estimate stage-specific one-year net survival and the excess hazard up to 18months after diagnosis, using flexible parametric models on the log cumulative excess hazard scale. RESULTS: One-year survival was 69% in the UK, 72% in Denmark and 74-75% elsewhere. In Denmark, 74% of patients were diagnosed with FIGO stage III-IV disease, compared to 60-70% elsewhere. International differences in survival were evident at each stage of disease; women in the UK had lower survival than in the other four countries for patients with FIGO stage III-IV disease (61.4% vs. 65.8-74.4%). International differences were widest for older women and for those with advanced stage or with no stage data. CONCLUSION: Differences in stage at diagnosis partly explain international variation in ovarian cancer survival, and a more adverse stage distribution contributes to comparatively low survival in Denmark. This could arise because of differences in tumour biology, staging procedures or diagnostic delay. Differences in survival also exist within each stage, as illustrated by lower survival for advanced disease in the UK, suggesting unequal access to optimal treatment. Population-based data on cancer survival by stage are vital for cancer surveillance, and global consensus is needed to make stage data in cancer registries more consistent. |
| | |
Authors:
|
Camille Maringe; Sarah Walters; John Butler; Michel P Coleman; Neville Hacker; Louise Hanna; Berit J Mosgaard; Andy Nordin; Barry Rosen; Gerda Engholm; Marianne L Gjerstorff; Juanita Hatcher; Tom B Johannesen; Colleen E McGahan; David Meechan; Richard Middleton; Elizabeth Tracey; Donna Turner; Michael A Richards; Bernard Rachet; |
Related Documents
:
|
10519317 - Chlamydia pneumoniae may be associated with lung cancer. preliminary report on a seroep... 22274547 - Therapeutic outcome and prognosis in young patients with papillary and follicular thyro... 15731117 - Transcriptional targets of the chromatin-remodelling factor smarca4/brg1 in lung cancer... 22887467 - Human papillomavirus modifies the prognostic significance of t stage and possibly n sta... 18575757 - Combined therapy using suicide gef gene and paclitaxel enhances growth inhibition of mu... 19826447 - Cancer risk evaluation in psoriasis: in search of the holy grail? |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-6-27 |
Journal Detail:
|
Title: Gynecologic oncology Volume: - ISSN: 1095-6859 ISO Abbreviation: - Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-7-3 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0365304 Medline TA: Gynecol Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2012. Published by Elsevier Inc. |
Affiliation:
|
Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Physicochemical analysis of structural changes in DNA modified with glucose.
Next Document: Sensory pits - enigmatic sense organs of the nymphs of the planthopper Issus coleoptratus (Auchenorr...